泰達生物(08189.HK)1,086萬人幣悉售天津阿爾發30.3%股權
泰達生物(08189.HK)公布,於昨日(28日)訂立股權轉讓協議,按現金代價1,086萬元人民幣(下同),向買方出售天津阿爾發30.2653%股權。於完成後,公司將不再持有天津阿爾發任何股權。為保證股權轉讓協議的按期履行,公司與買方及天津胡楊林分別簽訂了股權質押協議。
泰達生物指,自2014年以來,天津阿爾發一直處於虧損狀態,鑒於天津阿爾發之未來前景存在不確定性,董事會認為,出售事項為公司變現其於天津阿爾發投資之好機會,預期出售事項將獲得691.22萬元收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.